- Mr. Shad Good brings
nearly 20 years of medical device sales and leadership experience,
including as U.S. Senior Director of Sales at a global leader in
minimally invasive breast diagnostic and therapeutic
systems
- Immediate responsibility is to build out the sales
infrastructure as the Company awaits the FDA response to its
regulatory filing for early-stage low risk breast cancer in
patients who are at high risk for surgery as well as the FDA's
response to the final ICE3 results which are due in
2024
CAESAREA, Israel, Aug. 28,
2023 /PRNewswire/ -- IceCure Medical
Ltd. ("IceCure" or the "Company") (NASDAQ: ICCM) developer of
the ProSense® System, a minimally-invasive cryoablation technology
that destroys tumors by freezing as an alternative to surgical
tumor removal, announced today the appointment of Mr. Shad Good, a seasoned healthcare executive, as
Vice President of Sales for North
America. In this newly created position, Mr. Good will
report directly to the Chief Executive Officer of the Company and
his primary responsibility will be to build out a sales
infrastructure in anticipation of a broader commercialization of
Company's ProSense System in the U.S. and Canada.
Mr. Good, a proven and results-oriented executive, has worked
with global market leaders as well as high-growth medium sized
businesses. He was most recently VP of Sales at UV Concepts
Inc. Prior, he served as Senior Director of Sales, U.S., at
Devicor Medical Products, Inc. (Mammotome), an operating company of
Dahaner Corporation, where he consistently exceeded sales
expectations for the company's minimally invasive breast diagnostic
and therapeutic devices which are sold in 45 countries. Mr. Good
led the sales for the company's minimally invasive breast biopsy
systems and built a sales organization for the successful launch of
an emerging technology—a wire-free device for lumpectomies. Prior
to his role as Director of Sales, Mr. Good held the position of
Director of Corporate Accounts with Devicor Medical Products, Inc.
He has also served as Regional Sales Manager at Devicor Medical
Products, now also a Dahaner Corporation, where he boosted sales in
Canada and exceeded sales goals in
the U.S.
"Having worked in medical device sales and specifically with
minimally invasive breast diagnostics and therapeutic systems, I'm
excited to be joining IceCure and to lead its sales campaign for
the ProSense System in the U.S.," Mr. Good stated. "I know this
market indication very well and believe ProSense can gain rapid
traction as a minimally invasive alternative to the standard of
care lumpectomy."
IceCure's Chief Executive Officer, Eyal
Shamir, commented, "Our review and recruitment process was
extensive given the importance of this newly-created position at
this juncture. I believe Shad is the right person for this very
important position. It is with great confidence and belief in his
indication-specific knowledge, skills, network, and proven sales
leadership track record that we have appointed him to lead
ProSense's sales in North America.
As we await the FDA's response to our De Novo application for
early-stage low risk breast cancer in patients who are at high risk
for surgery, we are taking the next step towards having a
well-executed go-to-market plan for ProSense with Shad on
board."
About IceCure Medical
IceCure (Nasdaq: ICCM) develops and markets ProSense®, an
advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward looking Statements
This press release contains forward looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses the
responsibilities of Mr. Good under his new role, including to build
out the sales infrastructure in anticipation broader
commercialization of ProSense in the U.S. and Canada and to
lead a highly effective sales campaign for ProSense in the U.S.;
Mr. Good's belief that ProSense can gain rapid traction as a
minimally invasive alternative to the standard of care lumpectomy;
and taking the next step towards having a well-executed
go-to-market plan for ProSense. . Because such statements deal with
future events and are based on IceCure's current expectations, they
are subject to various risks and uncertainties and actual results,
performance, or achievements of IceCure could differ materially
from those described in or implied by the statements in this press
release. The forward looking statements contained or implied in
this press release are subject to other risks and uncertainties,
many of which are beyond the control of the Company, including
those set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on
March 29, 2023, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kerhli
Phone: 310-625-4462
Logo :
https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-takes-next-major-initiative-as-it-prepares-to-accelerate-the-commercialization-of-prosense-in-us-and-canada-appoints-vp-of-sales-north-america-301911062.html
SOURCE IceCure Medical